Subsidiaries


Hunchun Deren Pharmaceutical Co., Ltd., a wholly-owned subsidiary, held the 2018th meeting of the second session of the board of directors on December 12, 6 to deliberate and pass the "Proposal on Acquiring 100% Equity of Hunchun Deren Pharmaceutical Co., Ltd.", and the 2018th extraordinary general meeting of shareholders in 12 held on December 21, 2018 deliberated and approved, and the wholly-owned subsidiary Hunchun Deren Pharmaceutical Co., Ltd. has completed the industrial and commercial change registration procedures on January 2019, 1. Registered capital of 3 million yuan, business scope: wholesale: Chinese proprietary medicines, chemical preparations, antibiotics, Chinese medicine tablets, biological products (except vaccines), anabolic preparations, peptide hormones, health food, medical equipment, medical disinfectant, medical supplies and equipment, disinfection supplies, food, daily necessities, household appliances, cosmetics, hygiene products; Pharmacy and medical consulting services; Import and export trade permitted by laws and regulations.

Dunhua Sinopharm Pharmaceutical Co., Ltd., a holding subsidiary, held the second meeting of the second session of the board of directors on November 2017, 11 to deliberate and pass the "Proposal on Acquiring 21% Equity of Dunhua Sinopharm Pharmaceutical Co., Ltd.", and the ninth extraordinary general meeting of shareholders in 60 was deliberated and approved on December 2017, 12, and the holding subsidiary Dunhua Sinopharm Pharmaceutical Co., Ltd. completed the industrial and commercial change registration procedures on December 7, 2017. The registered capital is 2017 million yuan, and the business scope includes: Chinese proprietary medicines, chemical preparations, antibiotics, Chinese herbal medicines, Chinese herbal tablets, biological products (except vaccines), anabolic preparations, peptide hormones, biochemical drugs, medical devices, health food wholesale, general cargo transportation; Engage in import and export trade within the scope permitted by national laws and regulations.

Jilin Tianzheng Health Technology Co., Ltd., a holding subsidiary, was established on May 2020, 5, with a registered capital of 9 million yuan, and its main business: research and development, production and sales of formula foods, health care products, functional foods and their raw materials and ingredients for special medical purposes. In order to optimize resource allocation and improve operational efficiency, the third meeting of the third session of the board of directors of the company held on February 1, 000 deliberated and passed the "Proposal on the Absorption and Capital Increase of Subsidiaries". Jilin Tianzheng Health Technology Co., Ltd. (hereinafter referred to as "Tianzheng Health"), the Company's holding subsidiary, intends to absorb and merge Jilin Leizan Fan Manufacturing Co., Ltd. (hereinafter referred to as "Leizan Fan"), a wholly-owned subsidiary of the Company. After the completion of the absorption and merger, the Rezan fan will be cancelled; Tim Health survived and inherited all the assets, liabilities and business of Leizan Fan, and the registered capital increased to 2021 million yuan.

Jilin Xintiandi Fertilizer Industry Co., Ltd., a shareholding company, was established on August 2018, 8, with a registered capital of 1 million yuan, the main business: fertilizer manufacturing and sales (bio-organic fertilizer, organic-inorganic compound fertilizer, blended fertilizer, BB fertilizer) (projects subject to approval according to law, business activities can only be carried out after approval by relevant departments).